Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

Eli Lilly's COVID-19 Combination Trial Meets Primary Endpoint of Lowering Recovery Time; Plans Emergency Use Authorization Filing

2:28PM ET 9/17/2020 MT Newswires
Eli Lilly (LLY) said Thursday initial data from more than 1,000 patients in a COVID-19 treatment trial of baricitinib in combination with Gilead Science's (GILD) remdesivir met the primary endpoint of reducing recovery time compared with just remdesivir.

The reduction in the median recovery time was approximately one day for the patient population, according to a statement. The study also met a key secondary endpoint comparing patient outcomes at Day 15 ranging from fully recovered to death.

Based on this data, which was released in conjunction with Incyte (INCY), Lilly plans to discuss a potential emergency use authorization with the US Food and Drug Administration and to explore similar options with other regulatory agencies such as Health Canada.

"If authorized for use in Canada, Lilly will propose that baricitinib be available through commercial channels and will work with hospitals and governments to ensure patient access," the company said.

Price: 152.07, Change: +1.11, Percent Change: +0.74